Showing 21 - 30 of 58
Persistent link: https://www.econbiz.de/10003823734
Persistent link: https://www.econbiz.de/10009661155
Persistent link: https://www.econbiz.de/10009667235
Persistent link: https://www.econbiz.de/10010337670
Persistent link: https://www.econbiz.de/10009231562
Persistent link: https://www.econbiz.de/10001065467
Persistent link: https://www.econbiz.de/10011569748
Persistent link: https://www.econbiz.de/10011702615
Persistent link: https://www.econbiz.de/10011822822
When compared against capecitabine alone, the addition of lapatinib has a cost-effectiveness ratio exceeding the threshold normally used by NICE. Compared with T + C, L + C is dominant in the base case and approximately equally likely to be cost-effective in probabilistic sensitivity...
Persistent link: https://www.econbiz.de/10010993884